IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
Interleukin-1 receptor antagonist (IL-1ra) has been shown to play a crucial role in the prevention of various inflammatory diseases. There is also convincing evidence that IL-1ra is able to counteract inflammatory effects of IL-1 members implicated in insulin resistance and diabetes. However, the use of knock-out animal models provides evidence to the contrary and the role of IL-1ra in obesity-linked anomalies remains controversial. This minireview gets an insight into recent findings on the implication of IL-1ra and its gene polymorphism in diabetes and obesity, discusses the potential dual effects of IL-1ra observed in different models, and comments on future directions.
Perrier
Stephane
S
Division of Molecular Physiology, MSI/WTB Complex, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
Darakhshan
Froogh
F
Hajduch
Eric
E
D000818:Animals; D003920:Diabetes Mellitus / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control; D007333:Insulin Resistance / Q000235:genetics; D053590:Interleukin 1 Receptor Antagonist Protein / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use; D007375:Interleukin-1 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D009765:Obesity / Q000235:genetics / Q000378:metabolism*; D011110:Polymorphism, Genetic
D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1